NCT02457910 - Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

August 8, 2022

Conditions

Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor NegativeProgesterone Receptor PositiveStage IV Breast CancerTriple-Negative Breast Carcinoma

Interventions

OTHER

Biomarker Analysis

Correlative studies

DRUG

Enzalutamide

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Taselisib

Given PO

Trial Locations (12)

15260

University of Pittsburgh, Pittsburgh

20007

Georgetown University, Washington D.C.

21218

John Hopkins University, Baltimore

27599

University of North Carolina, Chapel Hill

35249

University of Alabama, Birmingham, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

47405

Indiana University, Indianapolis

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

77030

Baylor Breast Center, Houston

02115

Dana Farber Cancer Institute, Boston

Unknown

University of Michigan, Ann Arbor